Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1739 • ACR Convergence 2021
SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials
Susan Manzi¹, Richard Furie², Eric Morand³, Yoshiya Tanaka⁴, Gabriel Abreu⁵, Catharina Lindholm⁵ and Raj Tummala⁶, ¹Allegheny Health Network, Pittsurgh, PA, ²Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ³Monash University, Melbourne, Australia, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity versus placebo in patients with moderate…
Abstract Number: 1757 • ACR Convergence 2021
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
Matthew Snyder¹, Angel Chen¹, Sonali Narain² and Galina Marder², ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital Program, New York, NY, ²Northwell Health, Great Neck, NY
Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus…
Abstract Number: 1905 • ACR Convergence 2021
CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
Jennifer Barnas¹, Jennifer Barnard², Cameron Baker², Nida Meednu², Andrew McDavid¹, R. John Looney¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…
Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Joseph Couto¹, Elisea Avalos-Reyes², Amanda McCarthy³, Olga Matlin⁴, Michele Hamburger⁵, Gerard Maher⁶ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Irving, TX, ³CVS Health, Greensboro, GA, ⁴CVS Health, Northbrook, IL, ⁵Frances Hamburger Institute, Hauppauge, NY, ⁶Frances Hamburger Institute, Hauppaugue, NY
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
Abstract Number: 0334 • ACR Convergence 2021
Association Between Systemic Lupus Erythematosus and Myasthenia Gravis: A Population-Based National Study
Sali Merjanah¹, Ann Igoe², David Kaelber³ and Robert Hal Scofield⁴, ¹Boston University, Boston, MA, ²OhioHealth Hospital, Mansfield, OH, ³The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are two autoimmune disorders that have a young female preponderance, relapsing-remitting course, and positive antinuclear antibodies.…
Abstract Number: 0353 • ACR Convergence 2021
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung⁵, Cherie Ng¹, Chandra Mohan⁶ and Chaim Putterman⁷, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU School of Medicine, New York, NY, ⁵Equillium, Inc., San Diego, CA, ⁶University of Houston, Houston, TX, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. While LN pathogenesis has yet to be…
Abstract Number: 0536 • ACR Convergence 2021
The EIF4 Translational Inhibitor Pateamine a Improves Immunological and Neurological Functions in BXSB.yaa Lupus Mice
Gonzalo Gómez-Hernández¹, Nieves Varela¹, Harini Bagavant², Guillermo Barturen¹, Marta E. Alarcon-Riquelme¹ and Maria Morell¹, ¹GENYO.Center for Genomics and Oncological Research, Granada, Spain, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance and activation of the immune response. Clinical manifestations are heterogeneous and…
Abstract Number: 0627 • ACR Convergence 2021
Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Emily Datyner¹, Manda Mitchell¹, Brooke Fine¹, Barron Patterson¹, T. Brent Graham¹ and Alaina Davis², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Depression is common and adversely affects health outcomes in adolescents and young adults with childhood-onset systemic lupus erythematous (cSLE).1,2 The aim of our quality…
Abstract Number: 0858 • ACR Convergence 2021
Effect of COVID Infection and COVID Vaccination on SLE Activity, Including Antiphospholipid Antibodies
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: SLE patients may have a particular propensity to some viral infections including zoster and CMV. International studies have suggested that prednisone and rituximab may…
Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
Abstract Number: 0893 • ACR Convergence 2021
Trajectories of Depressive Symptoms in Systemic Lupus Erythematosus over 7 Years
Seerat Chawla¹, Jiandong Su², Zahi Touma³ and Patricia Katz⁴, ¹University of California Los Angeles, Los Angeles, CA, ²University Health Network, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴University of California San Francisco, San Francisco, CA
Background/Purpose: Depression remains one of the most frequently observed psychiatric disorders in patients with SLE with a pooled prevalence of 35.0% (95% CI: 29.9%-40.3%). Nevertheless,…
Abstract Number: 1034 • ACR Convergence 2021
Racial/ethnic Differences in Lupus Pregnancy Outcomes over 1 Decade: A US National Study
Bella Mehta¹, Yiming Luo², Deanna Jannat-Khah³, Jiehui Xu⁴, Lisa Sammaritano³, Jane Salmon³, Michael Lockshin¹, Susan Goodman³ and Said Ibrahim⁵, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²National Institutes of Health, Bethesda, MD, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵Weill Cornell Medicine, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects women and minorities of childbearing age. Although maternal and fetal outcomes of pregnancy among women with SLE have…
Abstract Number: 1188 • ACR Convergence 2021
Sifting Through Complexity in a Methodological Manner: Identifying Key Items in Teaching Lupus to Medical Students Through Consensus
Julie Thomas¹, Michael Battistone², Kyle Register¹ and Andrea Barker², ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Creating a curriculum for teaching lupus to medical students is a challenge given the complexities and nuances of this systemic disease. Because lupus spans…
Abstract Number: 1272 • ACR Convergence 2021
Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
Christopher Bell¹, Shirley Huang¹, Meg Wang², Maral DerSarkissian², Mei Sheng Duh², Bhavna Dhillon³, Carlyne Averell¹, Bernie Rubin¹ and Daniel Wallace⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Analysis Group, Boston, MA, ³United Rheumatology, Hauppauge, NY, ⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: SLE is a chronic, autoimmune disease affecting multiple organ systems, and characterized by fluctuating disease activity. Many SLE disease measures may be impractical for…
Abstract Number: 1288 • ACR Convergence 2021
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Mia Rodziewicz¹, Sarah Dyball¹, Stephen McDonald¹, Emily Sutton¹, Ben Parker¹, The British Isles Lupus Assessment Group² and Ian N. Bruce¹, ¹University of Manchester, Manchester, United Kingdom, ²Lupus Trust, London
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of infection compared to the general population. We aimed to assess the early risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].